Primary human hepatocytes (PHH), available through LifeNet Health LifeSciences, are the gold standard for in vitro evaluation of metabolism, drug-drug interaction, and toxicity studies. Protecting cell viability during the thawing protocol is critically important to achieve maximum post-thaw PHH yield. Traditionally, thawing medium has required storage at -20^oC to maintain stability over time. LifeNet Health has developed a new and improved thaw medium, with stable storage at 4^oC, that is optimized to maximize post-thaw PHH yield and viability consistently over long-term storage.

Benefits include:

• Our new optimized thawing medium maximizes the number of hepatocytes recovered after cryopreservation by an average of 34%.
• The new formulation eliminates the need for a filtration step, making it easier than ever to use.
• Extended shelf life provides greater flexibility in workflow timelines.

Use of our new thaw medium versus the old frozen thaw medium increased the post-thaw yield of PHHs for three separate lots with an average increase of 34%.

The post-thaw PHH yield and viability after using the new thaw medium are consistent over time, through 13 months of storage, demonstrating the stability of the new thaw medium stored at 4^oC.